PubMed Health⌕ Search

PubMed · 14499534

Fluoride in UK rivers.

Abstract

Fluoride concentrations in eastern UK rivers (the Humber, Tweed, Wear, Great Ouse and Thames) are described based on information collected within the Land-Ocean Interaction Study (LOIS) and by the Environment Agency (EA) of England and Wales. The results show varied fluoride concentrations across the region, with a range from <0.01 to >10 mg l(-1); and mean, median and range in mean concentrations of 0.30, 0.21 and 0.05-3.38 mg l(-1) (excluding one outlier point), respectively. Within the main rivers and tributaries, the mean fluoride concentration varied from approximately 0.5 to over 2 mg l(-1) and the highest values occurred within the Don basin (Don, Dearne and Rother) and parts of the Trent basin (upper Tame and mid-upper Derbyshire Derwent) in highly industrialised and urbanised areas (Sheffield and Rotherham in the Don basin; Birmingham and Derby on the Trent). For localised inputs to the rivers, fluoride concentrations were slightly higher, and considerably higher in one outlier case. Correspondingly, the other rivers examined typically had mean fluoride concentrations between approximately 0.2 and 0.5 mg l(-1), but fluoride concentrations were lower in the headwater areas. As there is much less information on fluoride levels in upland areas, extensive data collected as part of an acid waters survey are used to show that fluoride concentrations are generally less than 0.1 mg l(-1) for the upland UK. The data are summarised in terms of both fluoride concentrations and flux, and the values are cross-referenced to other determinands collected within LOIS. The high positive correlation with boron and negative correlation with flow show the importance of point source (sewage) inputs of fluoride, while strong positive correlations between fluoride and barium indicate the relative importance of vein mineralisation in the bedrock in supplying fluoride to the waters of the Yorkshire Ouse and its tributaries. There seems to be some process that limits the fluoride concentrations within the more contaminated rivers, and this is indicated by a negative upper bound between fluoride and calcium. The waters are undersaturated with respect to fluorite and oversaturated with respect to calcium fluoro-phosphates. This upper bound may reflect either physical controls, such as the availability and size of point and diffuse sources for fluoride coupled to mixing of these sources with rain and soil runoff of low concentration, or solubility controls for a pure or mixed-phase mineral that cannot be specified here.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Colin Neal, Margaret Neal, Helen Davies, Jennifer Smith. 2003-10-01. Fluoride in UK rivers.. https://doi.org/10.1016/s0048-9697(03)00104-9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗